title: Highly efficient lentiviral gene transfer in CD34+ and CD34+/38-/lin- cells from mobilized peripheral blood after cytokine prestimulation.
abstract: Because mobilized peripheral blood (mPB) represents an attractive source of cells for gene therapy, we investigated lentiviral gene transfer in CD34(+) cells and the stem/progenitor-cell-enriched CD34(+)/38(-)/lin(-) cell subset isolated from mPB. In this study, we used an optimized third-generation self-inactivating lentiviral vector containing both the central polypurine tract and the woodchuck hepatitis posttranscriptional regulatory element sequences and encoding enhanced green fluorescent protein (EGFP) under the control of the elongation factor lalpha promoter. This lentivector was first used to compare multiplicity of infection (MOI)-dependent gene transfer efficiency in cord blood (CB) versus mPB CD34(+)-derived cells, colony-forming cells (CFCs), and long-term culture-initiating cells (LTC-ICs). Results showed a difference in the percentage of transduced cells particularly significant at low MOIs. A plateau was reached where 15% and 25% of CB and mPB cells, respectively, remained refractory to lentiviral trans-duction. Effects of a cytokine prestimulation period (18 hours) with interleukin-3, stem cell factor, Flt-3 ligand, and thrombopoietin were then analyzed in total cells, CFCs, and LTC-ICs derived from mPB CD34(+) cells. Transduction levels in those conditions demonstrated a two- and fourfold increase in CFCs and LTC-ICs, respectively, compared with unstimulated (<3 hours) control cells. Moreover, using the same transduction protocol, we were able to efficiently transduce CD34(+)/38(-)/lin(-) cells isolated from mPB, with up to >85% of colonies derived from LTC-ICs expressing EGFP and gene transfer levels remaining stable for 10 weeks in liquid culture. We therefore demonstrate a highly efficient gene transfer in this therapeutically relevant target cell population.
authors.affiliation: Federative Research Institute 66, Bordeaux, France.
authors.forename: Fabien
authors.initials: F
authors.lastname: Géronimi
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Richard
authors.forename: Isabelle
authors.initials: I
authors.lastname: Redonnet-Vernhet
authors.forename: Isabelle
authors.initials: I
authors.lastname: Lamrissi-Garcia
authors.forename: Magalie
authors.initials: M
authors.lastname: Lalanne
authors.forename: Cécile
authors.initials: C
authors.lastname: Ged
authors.forename: François
authors.initials: F
authors.lastname: Moreau-Gaudry
authors.forename: Hubert
authors.initials: H
authors.lastname: De Verneuil
mesh_terms: D036541:ADP-ribosyl Cyclase / Q000096:biosynthesis*; D051997:ADP-ribosyl Cyclase 1; D015703:Antigens, CD / Q000096:biosynthesis*; D018952:Antigens, CD34 / Q000096:biosynthesis*; D002460:Cell Line; D016207:Cytokines / Q000378:metabolism*; D005312:Fetal Blood / Q000378:metabolism; D005434:Flow Cytometry; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors; D049452:Green Fluorescent Proteins; D006801:Humans; D007377:Interleukin-3 / Q000378:metabolism; D016086:Lentivirus / Q000235:genetics*; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008164:Luminescent Proteins / Q000378:metabolism; D008562:Membrane Glycoproteins; D008565:Membrane Proteins / Q000378:metabolism; D020648:Peptide Elongation Factor 1 / Q000378:metabolism; D011401:Promoter Regions, Genetic; D011533:Proviruses / Q000235:genetics; D011687:Purines / Q000737:chemistry; D013926:Thrombopoietin / Q000378:metabolism; D013997:Time Factors
chemical_list: D015703:Antigens, CD; D018952:Antigens, CD34; D016207:Cytokines; D007377:Interleukin-3; D008164:Luminescent Proteins; D008562:Membrane Glycoproteins; D008565:Membrane Proteins; D020648:Peptide Elongation Factor 1; D011687:Purines; C084881:flt3 ligand protein; D049452:Green Fluorescent Proteins; D013926:Thrombopoietin; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1; C030985:purine